Big Health announced on 8 August it has received US Food and Drug Administration clearance for its digital therapeutic (DTx), SleepioRx, for treating chronic insomnia as an adjunct to usual care for patients ages 18 and older.
Sleepio, a six-week digital program to help people improve quality of sleep, had already been recommended by the National Institute for Health and Excellence (NICE) as an effective alternative to sleeping pills in the UK and has been widely available at no cost to all residents in
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?